Axogen (Axogen) Retained Earnings : $-281.3 Mil (As of Dec. 2023)

View and export this data going back to 1986. Start your Free Trial

What is Axogen Retained Earnings?

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Axogen's retained earnings for the quarter that ended in Dec. 2023 was $-281.3 Mil.

Axogen's quarterly retained earnings declined from Jun. 2023 ($-273.3 Mil) to Sep. 2023 ($-277.4 Mil) and declined from Sep. 2023 ($-277.4 Mil) to Dec. 2023 ($-281.3 Mil).

Axogen's annual retained earnings declined from Dec. 2021 ($-230.6 Mil) to Dec. 2022 ($-259.6 Mil) and declined from Dec. 2022 ($-259.6 Mil) to Dec. 2023 ($-281.3 Mil).

Axogen Retained Earnings Historical Data

The historical data trend for Axogen's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Axogen Retained Earnings Chart

Axogen Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Retained Earnings

Get a 7-Day Free Trial

-179.86

-203.65

-230.63

-259.58

-281.30

Axogen Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Retained Earnings	Get a 7-Day Free Trial															-259.58	-266.65	-273.31	-277.40	-281.30

Axogen Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Axogen (NAS:AXGN) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

Axogen (Axogen) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » Axogen Inc (NAS:AXGN) » Definitions » Retained Earnings

Comparable Companies

Traded in Other Exchanges

LT3:Germany

Address

13631 Progress Boulevard, Suite 400, Alachua, FL, USA, 32615

Website

https://www.axogeninc.com

Axogen Inc is engaged in the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. The company provides clinically, economically effective repair solutions for surgeons and health care providers. Its products include Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard Nerve Cap, and Avive Soft Tissue Membrane. It also offers an Axotouch Two-Point Discriminator used to measure the innervation density of any surface area of the skin. Its products are available in the United States, Canada, Germany, the United Kingdom, Spain, South Korea, and several other countries.

Executives

Peter J Mariani	officer: Chief Financial Officer	C/O GUIDANT CORP, 111 MONUMENT CIRCLE #2900, INDIANAPOLIS IN 46204-5129
Amy Mcbride Wendell	director	COVIDIEN LTD., 15 HAMPSHIRE STREET, MANSFIELD MA 02048
Burke William P. Mr.	director	HAEMONETICS CORPORATION, 400 WOOD ROAD, BRAINTREE MA 02184
Guido J Neels	director	C/O GUIDANT CORP, 111 MONUMENT CIRCLE #2900, INDIANAPOLIS IN 46204-5129
Gregory Gene Freitag	director	13631 PROGRESS BLVD., ALACHUA FL 32615
Marc A Began	officer: EVP & General Counsel	C/O ABIOMED, INC., 22 CHERRY HILL DRIVE, DANVERS MA 01923
Joseph A. Tyndall	director	13631 PROGRESS BLVD., SUITE 400, ALACHUA FL 32615
John Johnson	director	DENDREON CORPORATION, 1301 2ND AVENUE, SEATTLE WA 98101
Karen L. Zaderej	director, officer: CEO	AXOGEN INC., 13859 PROGRESS BLVD, SUITE 100, ALACHUA FL 32615
Michael Patrick Donovan	officer: VP Operations	C/O AXOGEN, INC., 13631 PROGRESS BLVD. SUITE 400, ALACHUA FL 32615
Maria D. Martinez	officer: Chief Human Resources Officer	C/O AXOGEN INC., 13631 PROGRESS BLVD, SUITE 400, ALACHUA FL 32615
Paul Thomas	director	ONE MILLENNIUM WAY, BRANCHBURG NJ 08876
Alan M Levine	director	C/O AXOGEN, INC., 13631 PROGRESS BLVD. - SUITE 400, ALACHUA FL 32615
Mark Stephen Gold	director	13859 PROGRESS BLVD SUITE 100, ALACHUA FL 32615
Quentin S. Blackford	director	7475 LUSK BLVD., SAN DIEGO CA 92121